For Q3 2018, one of our picks is AMRN as a run-up play before data read-out. They have an approved drug for cardiovascular health and...

At Amp, we research biopharma companies primarily with valuations between $200M and $5B, who have upcoming catalyst events in the next 12...

The market has been very tough on small cap companies developing novel anti-microbials (e.g. antibiotics) since this past fall (See CDTX...

As the annual meeting for the American Association of Cancer Research kicks off this weekend and runs into early next week, we have been...